Upload
april-casey
View
56
Download
3
Tags:
Embed Size (px)
DESCRIPTION
Expanding the PsA Armamentarium. GRAPPA Treatment Recommendations for Psoriatic Arthritis. Controlled Trials of DMARDs in Psoriatic Arthritis. Anti-TNF Therapies in PsA ACR and PASI Responses. Anti-TNFs in PsA Other Outcomes. Current RA Therapies: Can They Be Used in PsA?. - PowerPoint PPT Presentation
Citation preview
Expanding the PsA Armamentarium
GRAPPA Treatment Recommendations for Psoriatic Arthritis
Controlled Trials of DMARDs in Psoriatic Arthritis
Anti-TNF Therapies in PsAACR and PASI Responses
Anti-TNFs in PsAOther Outcomes
Current RA Therapies: Can They Be Used in PsA?
Abatacept in PsAACR and PASI Responses at 169 Days
Emerging Therapies for PsA
Emerging Therapies for PsA (cont)
T-Cell Differentiation Pathways
IL-23 and Resident T Cells Promote Enthesitis and Osteoproliferation
Ustekinumab Inhibits IL-12 and IL-23 by Targeting the p40 Subunit
PSUMMIT 1: Ustekinumab (IL-12/23i) in Psoriatic Arthritis
ACR20/50/70 Responders at Week 24
PSUMMIT2Efficacy of Ustekinumab in Psoriatic Arthritis at
24 Weeks
Change From Baseline in Modified Total vdH-S Score at 24 Weeks
TH17 CellsElevated in Patients With Psoriatic
Arthritis
Psoriatic Arthritis Synoviocytes Express High Levels of IL-17RA
IL-17 Inhibitors in Development for PsA
Efficacy of IL-17 Inhibitors in Plaque Psoriasis
BrodalumabACR Responses at 24 Weeks
Mean Change in DAS28 to 52 WeeksObserved Analysis
Mean Change From Baseline in Dactylitis and Enthesitis
Observed Analysis
IL-6 Cell Types and Biologic Activities
Cytokine Signaling Pathways
ApremilastPDE4 inhibitor
PALACE 1Apremilast in PsA
Efficacy of Tofacitinib in Psoriasis
Abbreviations
Abbreviations (cont)
Abbreviations (cont)
References
References (cont)
References (cont)
References (cont)
References (cont)
References (cont)
References (cont)
References (cont)
References (cont)